. 2014 Jun 13;5(12):4529–4542. doi: 10.18632/oncotarget.2102

Table 2. The reversal efficacy of Icotinib in ABCG2-mediated drug resistance in ABCG2-transfected cell lines.

	IC₅₀ ± SD^a (μM)
Compounds	HEK293/pcDNA3.1	(RF)^b	ABCG2-482-R2	(RF)^b	ABCG2-482-G2	(RF)^b	ABCG2-482-T7	(RF)^b
Mitoxantrone (μM)	0.0557 ± 0.0028	1.0	0.5754 ± 0.0460	10.3	1.7045 ± 0.1364	30.6	1.1045 ± 0.0884	19.8
+ Icotinib 1.0 μM	0.0533 ± 0.0037	1.0	0.3438 ± 0.0309^*	6.2	0.7934 ± 0.0714^*	14.3	0.5524 ± 0.0497^*	9.9
+ Icotinib 5.0 μM	0.0503 ± 0.0040	0.9	0.0537 ± 0.0027^*	1.0	0.0701 ± 0.0035^*	1.3	0.0687 ± 0.0034^*	1.2
+ FTC 5.0 μM	0.0491 ± 0.0022	0.9	0.0564 ± 0.0023^*	1.0	0.0645 ± 0.0026^*	1.2	0.0632 ± 0.0025^*	1.1

SN-38 (μM)	0.0070 ± 0.00035	1.0	0.1885 ± 0.0151	27.1	0.2494 ± 0.0200	35.8	0.2095 ± 0.0168	30.1
+ Icotinib 1.0 μM	0.0067 ± 0.0005	1.0	0.0612 ± 0.0055^*	8.8	0.0811 ± 0.0073^*	11.7	0.0750 ± 0.0068^*	10.8
+ Icotinib 5.0 μM	0.0063 ± 0.0005	0.9	0.0087 ± 0.0004^*	1.2	0.0080 ± 0.0004^*	1.2	0.0077 ± 0.0005^*	1.1
+ FTC 5.0 μM	0.0061 ± 0.0003	0.9	0.0075 ± 0.0003^*	1.1	0.0078 ± 0.0003^*	1.1	0.0078 ± 0.0003^*	1.1

Cisplatin (μM)	1.6700 ± 0.0835	1.0	1.7045 ± 0.1364	1.0	1.6045 ± 0.1284	1.0	1.6704 ± 0.1336	1.0
+ Icotinib 5.0 μM	1.5980 ± 0.1119	1.0	1.6662 ± 0.1500	1.0	1.5524 ± 0.1397	0.9	1.5500 ± 0.0775	0.9
+ FTC 5.0 μM	1.5098 ± 0.1208	0.9	1.5801 ± 0.0790	0.9	1.6873 ± 0.0844	1.0	1.5400 ± 0.1001	0.9

^a.

IC₅₀ values are represented the mean ± standard deviation (SD).

^b.

Resistance fold (RF) was calculated by the IC₅₀ values for different substrates, and cisplatin of resistant cell lines, divided by the IC₅₀ values for the respective control without the reversing agents, or the resistant cell lines in the presence or absence of Icotinib or FTC, divided by the IC50 values for different substrates, and cisplatin of respective control without the reversing agents.

. P < 0.05, versus the control group.